Glaucoma: Current and New Therapeutic Approaches

Overview

Journal Biomedicines

Specialty Biomedical Engineering

Date 2024 Sep 28

PMID 39335514

Authors

Hsin-Pei Lee

Ta-Hsin Tsung

Yu-Chien Tsai

Yi-Hao Chen

Da-Wen Lu

Affiliations

Soon will be listed here.

Abstract

Glaucoma is identified by the loss of retinal ganglion cells (RGCs). The primary approach to managing glaucoma is to control intraocular pressure (IOP). Lately, there has been an increasing focus on neuroprotective therapies for glaucoma because of the limited effectiveness of standard methods in reducing IOP and preventing ongoing vision deterioration in certain glaucoma patients. Various drug-based techniques with neuroprotective properties have demonstrated the ability to decrease the mortality of retinal ganglion cells. This study will analyze the currently recommended drug-based techniques for neuroprotection in the prospective treatment of glaucoma.

References

Weinreb R, Liebmann J, Cioffi G, Goldberg I, Brandt J, Johnson C . Oral Memantine for the Treatment of Glaucoma: Design and Results of 2 Randomized, Placebo-Controlled, Phase 3 Studies. Ophthalmology. 2018; 125(12):1874-1885. DOI: 10.1016/j.ophtha.2018.06.017. View

Schuster A, Erb C, Hoffmann E, Dietlein T, Pfeiffer N . The Diagnosis and Treatment of Glaucoma. Dtsch Arztebl Int. 2020; 117(13):225-234. PMC: 7196841. DOI: 10.3238/arztebl.2020.0225. View

Li S, Chen L, Fu Y . Nanotechnology-based ocular drug delivery systems: recent advances and future prospects. J Nanobiotechnology. 2023; 21(1):232. PMC: 10362606. DOI: 10.1186/s12951-023-01992-2. View

Park J, Yoo C, Chung H, Kim Y . Effect of prostaglandin analogues on anterior scleral thickness and corneal thickness in patients with primary open-angle glaucoma. Sci Rep. 2021; 11(1):11098. PMC: 8160208. DOI: 10.1038/s41598-021-90696-4. View

Olson M . Applications for ROCK kinase inhibition. Curr Opin Cell Biol. 2008; 20(2):242-8. PMC: 2377343. DOI: 10.1016/j.ceb.2008.01.002. View

Riento K, Ridley A . Rocks: multifunctional kinases in cell behaviour. Nat Rev Mol Cell Biol. 2003; 4(6):446-56. DOI: 10.1038/nrm1128. View

Cooke Bailey J, Loomis S, Kang J, Allingham R, Gharahkhani P, Khor C . Genome-wide association analysis identifies TXNRD2, ATXN2 and FOXC1 as susceptibility loci for primary open-angle glaucoma. Nat Genet. 2016; 48(2):189-94. PMC: 4731307. DOI: 10.1038/ng.3482. View

Popa Cherecheanu A, Garhofer G, Schmidl D, Werkmeister R, Schmetterer L . Ocular perfusion pressure and ocular blood flow in glaucoma. Curr Opin Pharmacol. 2012; 13(1):36-42. PMC: 3553552. DOI: 10.1016/j.coph.2012.09.003. View

Chong R, Osborne A, Conceicao R, Martin K . Platelet-Derived Growth Factor Preserves Retinal Synapses in a Rat Model of Ocular Hypertension. Invest Ophthalmol Vis Sci. 2016; 57(3):842-52. DOI: 10.1167/iovs.15-17864. View

10.

Choquet H, Wiggs J, Khawaja A . Clinical implications of recent advances in primary open-angle glaucoma genetics. Eye (Lond). 2019; 34(1):29-39. PMC: 7002426. DOI: 10.1038/s41433-019-0632-7. View

11.

Yucel Y, Gupta N . Glaucoma of the brain: a disease model for the study of transsynaptic neural degeneration. Prog Brain Res. 2008; 173:465-78. DOI: 10.1016/S0079-6123(08)01132-1. View

12.

Wilcock G, Mobius H, Stoffler A . A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). Int Clin Psychopharmacol. 2002; 17(6):297-305. DOI: 10.1097/00004850-200211000-00005. View

13.

Caprioli J, Coleman A . Blood pressure, perfusion pressure, and glaucoma. Am J Ophthalmol. 2010; 149(5):704-12. DOI: 10.1016/j.ajo.2010.01.018. View

14.

Miguel-Hidalgo J, Alvarez X, Cacabelos R, Quack G . Neuroprotection by memantine against neurodegeneration induced by beta-amyloid(1-40). Brain Res. 2002; 958(1):210-21. DOI: 10.1016/s0006-8993(02)03731-9. View

15.

Casson R . Possible role of excitotoxicity in the pathogenesis of glaucoma. Clin Exp Ophthalmol. 2006; 34(1):54-63. DOI: 10.1111/j.1442-9071.2006.01146.x. View

16.

Tezel G . Immune regulation toward immunomodulation for neuroprotection in glaucoma. Curr Opin Pharmacol. 2012; 13(1):23-31. PMC: 3529855. DOI: 10.1016/j.coph.2012.09.013. View

17.

Qian K, Gu Y, Zhao Y, Li Z, Sun M . Citicoline protects brain against closed head injury in rats through suppressing oxidative stress and calpain over-activation. Neurochem Res. 2014; 39(7):1206-18. DOI: 10.1007/s11064-014-1299-x. View

18.

Doucette L, Rasnitsyn A, Seifi M, Walter M . The interactions of genes, age, and environment in glaucoma pathogenesis. Surv Ophthalmol. 2015; 60(4):310-26. DOI: 10.1016/j.survophthal.2015.01.004. View

19.

Zhang X, Tohari A, Marcheggiani F, Zhou X, Reilly J, Tiano L . Therapeutic Potential of Co-enzyme Q10 in Retinal Diseases. Curr Med Chem. 2017; 24(39):4329-4339. DOI: 10.2174/0929867324666170801100516. View

20.

Baudouin C, Kolko M, Melik-Parsadaniantz S, Messmer E . Inflammation in Glaucoma: From the back to the front of the eye, and beyond. Prog Retin Eye Res. 2020; 83:100916. DOI: 10.1016/j.preteyeres.2020.100916. View